syringe

Menactra (Sanofi) Antitrust Settlement

PLEASE NOTE: THE FILING DEADLINE TO SUBMIT A CLAIM TO THIS SETTLEMENT HAS PASSED. MCAG WILL UPDATE CLIENTS ACCORDINGLY ONCE INFORMATION IS AVAILABLE ON DISTRIBUTIONS FROM THIS SETTLEMENT.

Menactra Antitrust Litigation Settlement - Castro, et al. v. Sanofi Pasteur Inc., No. 11-7178

Settlement Fund:            $61,500,000
Settlement Period:          March 1, 2010 – December 31, 2014
Claim Filing Deadline:    February 20, 2018


Overview

The Court overseeing the Menactra (Sanofi) Settlement has preliminarily approved a $61.5 million settlement. Class Members such as physicians, medical practices, and health systems who bought Menactra directly from Sanofi claim that they paid higher prices than they should have for quadrivalent meningococcal vaccines (“MCV4 Vaccines”). These vaccines inoculate against four strains of bacterial meningitis. The lawsuit alleged that the higher prices resulted from Sanofi engaging in anticompetitive conduct.


Eligibility

All persons or entities in the United States and its territories that purchased Menactra directly from defendant Sanofi Pasteur Inc. (“Sanofi”) or any of its divisions, subsidiaries, predecessors or affiliates, such as VaxServe, Inc., during the period from March 1, 2010 through and including December 31, 2014 (“Settlement Period”), and excluding all governmental entities, Sanofi, Sanofi’s divisions, subsidiaries, predecessors, and affiliates, Kaiser Permanente and the Kaiser Foundation (collectively “Kaiser”), and any purchases by entities buying Menactra pursuant to a publicly negotiated price (i.e., governmental purchasers).

Generally, you are included in this case as a Class Member if you:

  • Are a person or entity (such as a medical practice), in the United States and its territories; and
  • Purchased Menactra directly from Sanofi Pasteur Inc. or any of its divisions, subsidiaries, predecessors, or affiliates (such as VaxServe, Inc.) from March 1, 2010 through and including December 31, 2014.

Status

Approval of the Settlement was granted by the Court on October 20, 2017.

The deadline for eligible Class Members to submit a claim has been extended to February 20, 2018.


You Can Help to Optimize Your Claim

MCAG will submit claims into this settlement for eligible clients. The provision of information at your earliest convenience will be beneficial to optimize your claim.

A list of DEA numbers will help to ensure that all eligible purchases across your entire organization are included in your claim.

  • Typically, each facility has one DEA number.
    • Please provide DEA numbers for any of your physician practices if they are readily accessible.
  • A good source for retrieving this information within your organization is likely the Directory of Pharmacy Services, or someone in a similar position.

You may send information pertaining to DEA numbers to settlements@mcaginc.com.  An MCAG Account Manager can be reached at 800-355-0466 with any questions.

If you are not already enrolled in MCAG's Settlement Recovery Service, please contact an MCAG Account Manager to learn how to take advantage of our service prior to the February 20, 2018 claim filing deadline.